Amber Tong – Page 126 – Endpoints News

about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW

Amber Tong on LinkedIn

author articles

Annalisa Jenkins' next career chapter takes her back to Europe

8 years ago

Struggling Oncolytics Biotech signs $86.6M Asia deal with China's Adlai Nortye

8 years ago

Merck partners up on T-cell tech platform in $374M autoimmune deal; Turnstone taps BMS vet Mike Burgess for top R&D ...

8 years ago

Moderna kicks off mRNA cancer vaccine study; Biotech stocks were checked this month -- but that's a good thing

8 years ago

Alnylam's patisiran grabs EMA accelerated review; CRISPR Therapeutics, Casebia enter mRNA deal with CureVac

8 years ago

Celgene's Michael Pehl leaps up to lead role at Immunomedics; GSK nabs Hal Barron to helm R&D; Aimmune CEO to step ...

8 years ago

Roche gets EMA recommendation for Ocrevus; Anthem now covers Sarepta's exon-skipping Duchenne MD drug

8 years ago

Mary Szela resigns as CEO of Novelion; China is proving to be a rewarding market for AstraZeneca

8 years ago

Eyeing Duchenne MD cure, The Column Group gambles $40M on CRISPR/Cas9 startup Exonics

8 years ago

Mumbai-based Lupin gets FDA warning for two manufacturing sites; Ionis promotes inotersen head as new COO

8 years ago

Boasting in-license distribution model, Chinese EOC Pharma bags $32M series B funding for oncology products

8 years ago

Japanese CMO Fujifilm Diosynth spends extra $28M in US, UK mAb facilities

8 years ago

Say it with us: IQVIA is the new Quintiles and IMS Health

8 years ago

Biotech Peer Review: Magenta onboards five new VPs; BioInvent is hunting for a new CEO

8 years ago

As National Party Congress concludes, China’s FDA seeks to write widely-anticipated drug reforms into law

8 years ago

First page Previous page 123 124 125126